Los Angeles Capital Management
CRSP icon

Los Angeles Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Los Angeles Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4K Sell
300
-473
-61% -$24.9K ﹤0.01% 1846
2026
Q1 		$36.8K Buy
773
+60
+8% +$3.17K ﹤0.01% 1559
2025
Q4 		$43.6K Buy
+713
New +$42.7K ﹤0.01% 1647
2021
Q3 		– Sell
-1,277
Closed -$207K – 1494
2021
Q2 		$207K Buy
+1,277
New +$155K ﹤0.01% 1489

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Los Angeles Capital Management's CRSP Position: Q2 2026 in Review

Los Angeles Capital Management reduced its CRISPR Therapeutics (CRSP) stake by 61% in Q2 2026, selling an estimated $24.9K and leaving 300 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1846.

Los Angeles Capital Management first reported a position in CRSP in Q2 2021 and has held it in 4 quarters since. The position peaked at $207K in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Los Angeles Capital Management held 300 shares of CRISPR Therapeutics worth $16.4K as of Q2 2026.
  • Los Angeles Capital Management sold 473 CRISPR Therapeutics shares in Q2 2026, an estimated $24.9K.
  • CRISPR Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1846 holding.
  • Los Angeles Capital Management first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • Los Angeles Capital Management's CRISPR Therapeutics position peaked at $207K in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.